Preprint2025

Third-line S-1 or FOLFOX treatment in advanced pancreatic cancer who received gemcitabine+nab-paclitaxel and nanoliposomal-irinotecan+5-fluorouracil/leucovorin

DOI 10.21203/rs.3.rs-5801148/v1 ↗ OpenAlex, retrieved 5 November 2026

Published: 13 January 2025
Citations: 0
Type: Preprint
License: cc by

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try